openPR Logo
Press release

Measles Vaccine Market Trends and Forecast by 2025

06-16-2017 05:31 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Measles is a severe and infectious disease triggered by a virus. Early symptoms of the disease are fever, red eyes, runny nose, and cough. Later, red spots and tiny rashes are observed on skin. Measles is spread by a virus belonging to the paramyxovirus family, genus Morbillivirus. The diameter of virus is 120 nm to 250 nm. Measles only occurs in humans and not in animals. The measles virus first infects only the respiratory tract, then spreads throughout the body.

Browse through Measles Vaccine Market report to know what factors will shape the market by 2025:

Measles is one of the leading causes of death among children. According to the World Health Organization (in 1980), measles caused an estimated 2.6 million deaths each year. In 2015, approximately 134200 people died globally due to measles. MMR vaccines (combination of measles, mumps, and rubella vaccine) is given at the time of birth to prevent measles. It is an immunization vaccine and combination of live attenuated viruses of three diseases. In 2015, about 85% of world’s children received one dose of measles vaccine by birthday through routine health services.

The Centers for Disease Control and Prevention (CDC) recommended two doses of measles vaccine. One dose of measles vaccine is 93% effective, while two doses of vaccine is 97% effective in preventing measles. The first dose of measles vaccine is recommended at 12 months through 15 months of age, and the second dose at 4 years through 6 years. One dose of vaccination is recommended to adults who did not get vaccinated in childhood.

The measles vaccine market has been segmented based on product, application, end-user, and region. In terms of product, the market has been categorized into two types: mumps measles rubella vaccine, live (MMR-II) and mumps measles rubella and varicella virus vaccine (Proquad). MMR II (measles, mumps, and rubella virus vaccine live) is a live virus vaccine for vaccination against measles (rubeola), mumps, and rubella (German measles). MMR II is a sterile lyophilized preparation of live virus vaccine containing measles virus, mumps virus, and rubella virus. Proquad is the sterile lyophilized combination of live virus vaccine containing measles, mumps, rubella and varicella virus.

Based on application, the global measles vaccine market has been divided into pediatric vaccines and adult vaccines. Pediatric vaccines are given in two doses. First at the age of 15 months and second is before the age of six. Pediatric vaccines are more effective than adult vaccines. Adult vaccine is only single dose vaccine. According to CDC, adults born in 1957 or later who have not been vaccinated or have not had measles are recommended one dose of measles vaccine. The pediatric vaccines segment is estimated to account for major share of the global measles vaccine market.

In terms end-user, the global measles vaccine market has been segmented into hospitals, clinics, and vaccination centers. Measles vaccines are cost effective and easily available.

Geographically, the global measles vaccine market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to hold high market share of the global measles vaccine market owing to high awareness about the disease and vaccination in the region. Asia Pacific is expected to expand at a high CAGR during the forecast period driven by government initiatives for immunization against measles. Latin America and Middle East & Africa are expected to show significant growth during the forecast period. Growth in the regions is driven by low cost of vaccination. The cost of measles vaccination is less than US$ 1 in these regions.

Get accurate market forecast and analysis on the Measles Vaccine Market. Request a sample to stay abreast on the key trends impacting this market:

Key players in the global measles vaccine market are MedImmune, Johnson & Johnson Private Limited, Merck & Co., Inc., Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Astellas Pharma India Private Limited, CSL Limited, Emergent BioSolutions Inc., and GlaxoSmithKline plc, among others.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Measles Vaccine Market Trends and Forecast by 2025 here

News-ID: 583444 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases

More Releases for Measles

Measles Testing Market to be at Forefront by 2024
Global Measles Testing Market: Snapshot The global measles testing market is anticipated to showcase a record growth during the forecast period 2016–2024. This could be on account of the recent developments in the field of automation and most importantly, immunodiagnostic technology. There is an elevating awareness about measles across the globe and its outbreak especially in the developing countries of the world. New companies entering the market with novel ways of
Measles Vaccine
Measles Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Measles Vaccine Market Production and Demand Analysis 2019 to 2025 Measles Vaccine Market 2019 Manufacturing Analysis and Development Forecast 2025 Measles Vaccine Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025 Measles Vaccine Market to Insight By 2025: Top Key Vendors The global Measles Vaccine market is valued at million US$ in 2018 and will reach million US$ by the
Global Measles Market Report 2019 By Valuates Reports
Global Measles Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Measles industry. Measles is a highly contagious infectious disease caused by the measles virus. Symptoms usually develop 10–12 days after exposure to an infected person and last 7–10 days. Initial symptoms typically include fever, often greater than 40 °C (104 °F), cough, runny nose,
Measles Vaccine Market 2019-2025: Expansive implementation enhance growth
Measles Vaccine Market research report examines adoption trends, future growth potentials, key drivers, competitive outlook, restraints, opportunities, key challenges, Measles Vaccine industry ecosystem, and revenue chain analysis. This report presents a detailed analysis, market sizing, and forecasting up to 6 Year 2019-2025 for the emerging segment within the Measles Vaccine market. The report is thoroughly segmented by product type, application, vertical, and region. The points that are discussed within the
Measles Testing Market Size to Expand Significantly by 2024
Being one of the most common causes of death among kids, measles has become a global problem despite the fact that there are cost-effective and safe vaccines available for its prevention. This highly contagious disease killed an estimated 134,200 people in 2015, according to findings of the World Health Organization (WHO), which amounts to nearly 15 deaths on an hourly basis. However, growing awareness among the general population regarding vaccination and
Measles Therapeutic Clinical Trials Market Review, H2 2018
Summary “Measles Global Clinical Trials Review, H2, 2017" provides an overview of Measles clinical trials scenario. This report provides top line data relating to the clinical trials on Measles. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report